Blood Based Biomarkers For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Blood-based biomarkers represent a major advance in neurodegenerative disease diagnostics and monitoring, offering minimally invasive alternatives to cerebrospinal fluid (CSF) and neuroimaging biomarkers.
{{Infobox
|title=Blood-Based Biomarkers for Neurodegeneration
|category=Biomarker
|target=Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease
|sample=Blood (plasma, serum)
|method=ELISA, Simoa, Lumipulse
}}
- Minimally invasive: Easy collection
- Cost-effective: Lower than PET or CSF
- Repeatable: Suitable for monitoring
- Accessible: Can be used in primary care
- Method: Simoa, Lumipulse
- Changes: Decreased in AD
- Accuracy: AUC 0.80-0.90 vs amyloid PET
- Use: Screening, not diagnostic alone
- Method: Simoa, Elecsys
- Changes: Increased in AD
- Correlation: With brain amyloid burden
- Use: Diagnostic, disease progression
- Method: Simoa
- Changes: Increased in AD
- Performance: AUC >0.90 vs amyloid PET
- Specificity: Higher than p-tau181
- Method: Simoa
- Changes: Elevated early
- Use: Early detection, preclinical AD
- Method: Simoa
- Changes: Increased in AD
- Correlation: With disease progression
- Use: Monitoring, prognosis
- Method: Simoa
- Changes: Increased in AD
- Specificity: Lower than p-tau
- Method: ELISA
- Changes: Decreased total, increased oligomers
- Use: Diagnostic accuracy limited
- Method: Simoa
- Changes: Increased in PD
- Performance: Good discrimination from controls
- Method: RT-QuIC, PMCA
- Detects: Pathological α-synuclein
- Accuracy: High sensitivity in plasma
- Method: Simoa
- Changes: Increased in PD
- Correlation: With disease severity
- Use: Progression marker
- Method: Activity assay
- Changes: Reduced in GBA-PD
- Use: Risk stratification
- Method: Simoa
- Changes: Dramatically elevated in ALS
- Performance: High diagnostic accuracy
- Use: Diagnostic, prognostic
- Method: Simoa
- Changes: Increased in ALS
- Correlation: With disease progression
- Method: ELISA
- Changes: Increased in ALS
- Correlation: With progression rate
- Method: Simoa, TR-FRET
- Changes: Detectable in premanifest
- Correlation: With disease burden
- Use: Trial enrichment
- Method: Simoa
- Changes: Increased in HD
- Use: Disease progression marker
- Collection tubes (EDTA, heparin)
- Processing time
- Storage conditions
- Freeze-thaw cycles
- Assay platform
- Calibration
- Sensitivity
- Specificity
- Age-adjusted reference ranges
- Disease stage consideration
- Combined biomarker panels
- Screening in primary care
- Specialist referral
- Differential diagnosis
- Disease progression prediction
- Survival estimation
- Clinical trial enrichment
- Treatment response
- Disease progression
- Safety monitoring
- Ultra-sensitive detection
- Femtomolar sensitivity
- Leading platform for NfL, p-tau
- Lumipulse system
- Automated platforms
- High throughput
- Targeted proteomics
- Multiplex capability
- Reference method potential
The study of Blood Based Biomarkers For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Zetterberg H, et al. Nat Rev Neurol. 2023;19(12):727-740. PMID:37993565
[2] Hansson O, et al. Nat Med. 2024;30(1):42-53. PMID:38182618
[3] Blennow K, et al. Nat Rev Neurol. 2022;18(5):299-312. PMID:35228761
[4] Lewczuk P, et al. Nat Rev Neurol. 2024;20(1):5-19. PMID:38148391
[5] Ashton NJ, et al. Nat Rev Neurol. 2021;17(12):729-743. PMID:34556776
[6] Mollenhauer B, et al. Nat Rev Neurol. 2023;19(1):35-48. PMID:36473908
[7] Benatar M, et al. Nat Rev Neurol. 2022;18(10):625-637. PMID:36045394
[8] Wild EJ, et al. Nat Rev Neurol. 2024;20(2):89-101. PMID:38212348